JPS62224259A - Nourishing meal - Google Patents
Nourishing mealInfo
- Publication number
- JPS62224259A JPS62224259A JP61065901A JP6590186A JPS62224259A JP S62224259 A JPS62224259 A JP S62224259A JP 61065901 A JP61065901 A JP 61065901A JP 6590186 A JP6590186 A JP 6590186A JP S62224259 A JPS62224259 A JP S62224259A
- Authority
- JP
- Japan
- Prior art keywords
- albumin
- protein
- nutritional food
- meal
- nutritional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000012054 meals Nutrition 0.000 title abstract description 6
- 108010088751 Albumins Proteins 0.000 claims abstract description 25
- 102000009027 Albumins Human genes 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- 235000013336 milk Nutrition 0.000 claims abstract description 11
- 239000008267 milk Substances 0.000 claims abstract description 11
- 210000004080 milk Anatomy 0.000 claims abstract description 11
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 11
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 11
- 108010058846 Ovalbumin Proteins 0.000 claims abstract description 7
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims abstract description 3
- 235000016709 nutrition Nutrition 0.000 claims description 37
- 235000013305 food Nutrition 0.000 claims description 32
- 235000018102 proteins Nutrition 0.000 claims description 20
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 235000014633 carbohydrates Nutrition 0.000 claims description 7
- 235000021120 animal protein Nutrition 0.000 claims description 2
- 208000034767 Hypoproteinaemia Diseases 0.000 abstract description 7
- 208000003623 Hypoalbuminemia Diseases 0.000 abstract description 6
- 235000019621 digestibility Nutrition 0.000 abstract 1
- 230000000050 nutritive effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- -1 fatty acid ester Chemical class 0.000 description 5
- 235000003715 nutritional status Nutrition 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 108010073771 Soybean Proteins Proteins 0.000 description 4
- 235000019710 soybean protein Nutrition 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 108090000322 Cholinesterases Proteins 0.000 description 2
- 102000003914 Cholinesterases Human genes 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 229940048961 cholinesterase Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 208000009928 nephrosis Diseases 0.000 description 2
- 231100001027 nephrosis Toxicity 0.000 description 2
- 235000016236 parenteral nutrition Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000005974 protein supplement Nutrition 0.000 description 2
- 229940116540 protein supplement Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000008371 vanilla flavor Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000020882 elemental diet Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は栄養食に係り、殊に各種の疾患例えば肝障害(
肝硬変、慢性肝炎等)、腎障害(ネフローゼ、透析患者
等)、消化管障害(消化器潰瘍、吸収不良症候群等)、
悪性腫瘍等に起因して栄養状態不良となり、その結果低
蛋白血症や低アルブミン血症を呈している患者に与える
のに極めて好適な栄養食に係る。DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to nutritional foods, and particularly to nutritional foods for various diseases such as liver disorders (
liver cirrhosis, chronic hepatitis, etc.), renal disorders (nephrosis, dialysis patients, etc.), gastrointestinal disorders (gastrointestinal ulcers, malabsorption syndrome, etc.),
The present invention relates to a nutritional food that is extremely suitable to be given to patients who suffer from poor nutritional status due to malignant tumors or the like, and as a result exhibit hypoproteinemia or hypoalbuminemia.
本発明による栄養食は、上記のような患者用としてのみ
ならず、一般の健康人や成長期にある乳児、児童に対し
栄養補給及び筋肉強化を目的として与える場合にも好適
である。The nutritional food according to the present invention is suitable not only for patients as described above, but also for general healthy people, growing infants, and children for the purpose of nutritional supplementation and muscle strengthening.
(従来の技術及びその問題点)
従来、低蛋白血症や低アルブミン血症を改善するために
、非経口的方策としては静脈栄養又は経腸栄養による蛋
白及びアミノ酸の補給が行われており、又経口的方策と
しては高蛋白食又は蛋白補助剤の摂取が行われている。(Prior art and its problems) Conventionally, in order to improve hypoproteinemia and hypoalbuminemia, parenteral measures include supplementation of proteins and amino acids through parenteral nutrition or enteral nutrition. Oral strategies include ingestion of high protein foods or protein supplements.
患者が経口摂取不能の場合に、静脈栄養は有用であるが
、手技が繁雑であり、経済的な負担も大きく、又感染症
等の副作用発生の心配がある。経腸栄養による蛋白及び
アミノ酸の補給は感染症の心配がなく、経済的にも負担
が少ないが、長期にわたる経管栄養投与は患者にとって
苦痛であり、又下痢等の副作用を生じ易い。Parenteral nutrition is useful when a patient is unable to take oral intake, but it is a complicated procedure, imposes a large economic burden, and there is a concern that side effects such as infection may occur. Supplementation of protein and amino acids through enteral nutrition is free from infectious diseases and is less of an economic burden; however, long-term administration of enteral nutrition is painful for patients and tends to cause side effects such as diarrhea.
これらの非経口摂取と比較する場合に、経口摂取による
補給は容易であり、生理的に優れ、経済的な負担も少な
く、従って消化能力を有している患者に関しては有用性
が最も高−い。しかしながら、蛋白及びアミノ酸の経口
補給用として現在供されている高蛋白食乃至蛋白補助剤
は大豆蛋白を主体としたものが多く、消化吸収性、栄養
価及び嗜好性の面を考慮に入れる場合に、低蛋白血症や
低アルブミン血症の改善に有効であり且つ適切な経口栄
養食は存在しないのが実情である。When compared with these parenteral supplements, oral supplementation is easy, physiologically superior, and has less economical burden, and is therefore most useful for patients who have the ability to digest it. . However, many of the high-protein foods and protein supplements currently available for oral supplementation of protein and amino acids are mainly based on soybean protein. The reality is that there is no oral nutritional food that is effective and appropriate for improving hypoproteinemia and hypoalbuminemia.
(発明の目的)
従って、本発明の目的は経口摂取が容易であって、消化
吸収が良好であり、栄養価が高く、しかも嗜好性にも優
れており、その結果低蛋白血症や低アルブミン血症の改
善に有効な栄養食を提供することである。(Objective of the Invention) Therefore, the object of the present invention is to provide a product that is easy to take orally, has good digestion and absorption, has high nutritional value, and has excellent palatability, resulting in hypoproteinemia and low albuminemia. The aim is to provide nutritional food that is effective in improving blood pressure.
(目的を達成するための手段及び作用)本発明によれば
、上記の目的は、動物由来のアルブミンを主体とする蛋
白質と、糖質と、核酸とを含有している栄養食により達
成される。(Means and Effects for Achieving the Object) According to the present invention, the above object is achieved by a nutritional food containing protein, mainly albumin derived from an animal, carbohydrates, and nucleic acids. .
本発明による栄養食における量割合に関しては、上記蛋
白質を10−90%、上記糖質を 1−90%、また上
記核酸を0.5−10% とするのが適当である。Regarding the proportions in the nutritional food according to the present invention, it is appropriate that the protein be 10-90%, the carbohydrate be 1-90%, and the nucleic acid be 0.5-10%.
動物由来のアルブミンとしては乳アルブミン及び卵アル
ブミンの少なくとも一種であることできる。蛋白質とし
てこれらのアルブミン以外に動物性及び植物性蛋白の少
なくとも一種を含有していることができ、この場合に動
物性蛋白としてはカゼイン、ゼラチン及び卵白等を挙げ
ることができ、又植物性蛋白としては大豆蛋白及び小麦
蛋白等を挙げることができる。上記の動物性アルブミン
はそのアミノ酸組成において制限アミノ酸が存在しない
ので蛋白質として良質であり且つ肝臓で生合成されるア
ルブミンとほぼ同一の組成を有している。尚、乳アルブ
ミンはシスチン及びトリプトファン含量が高く且つアミ
ノ酸組成も良好であり、一方卵アルブミンも他の蛋白と
比較する場合に含量アミノ酸、殊にメチオニン含量が高
い点において優れている。The animal-derived albumin can be at least one of milk albumin and egg albumin. In addition to these albumins, the protein may contain at least one of animal and vegetable proteins, and in this case, the animal proteins include casein, gelatin, egg white, etc. Examples include soybean protein and wheat protein. The above-mentioned animal albumin has no limiting amino acids in its amino acid composition, so it is of high quality as a protein and has almost the same composition as albumin biosynthesized in the liver. Milk albumin has a high cystine and tryptophan content and a good amino acid composition, while egg albumin is also superior to other proteins in that it has a high amino acid content, especially methionine content.
従って、本発明による栄養食は患者に投与摂取される場
合に低蛋白血症や低アルブミン血症を有効に改善するこ
とができる。Therefore, the nutritional food according to the present invention can effectively improve hypoproteinemia and hypoalbuminemia when administered to a patient.
糖質としてはデンプン、デキストリン、マルトース、ソ
ルビット、果糖、ブドウ糖及び庶糖等を挙げることがで
きる。糖質の添加は糖質自体の補給のためのみならず、
栄養食原料の造粒性を良好ならしめ、更には造粒により
形成された粉末の溶解性を向上させる効果を有している
。Examples of carbohydrates include starch, dextrin, maltose, sorbitol, fructose, glucose, and sucrose. The addition of carbohydrates is not only for the purpose of replenishing the carbohydrates themselves;
It has the effect of improving the granulation properties of nutritional food raw materials and further improving the solubility of the powder formed by granulation.
核酸は生体内での蛋白の合成促進及び蛋白質代謝の元通
をもたらすために添加される。Nucleic acids are added to promote protein synthesis and normalize protein metabolism in vivo.
本栄養食を水、牛乳、ジュース、紅茶等に溶解させる場
合に溶解性を良好になす目的で、必要であれば乳化剤を
添加することができ、この乳化剤としてはポリグリセリ
ン脂肪酸エステルを用いるのが好ましい。When dissolving this nutritional food in water, milk, juice, black tea, etc., an emulsifier can be added if necessary to improve solubility. As the emulsifier, it is recommended to use polyglycerin fatty acid ester. preferable.
尚、本発明による栄養食には、上記の諸成分以外にも必
要に応じて各種の脂質、ビタミン類、ミネラル類等を添
加配合することができる。In addition to the above-mentioned components, various lipids, vitamins, minerals, etc. may be added to the nutritional food according to the present invention as required.
(発明の効果)
本発明による栄養食は、栄養不良の低蛋白血症患者や、
低アルブミン血症を伴う肝硬変、慢性肝炎、ネフローゼ
、大腸性潰瘍炎患者に経口摂取させる場合に栄養改善効
果及び病状の改善効果をもたらす。即ち、血清総蛋白及
びアルブミン値の上昇、体重の増加並びに浮腫の消失が
もたらされるのである。(Effects of the Invention) The nutritional food according to the present invention can be used for malnourished hypoproteinemic patients,
When orally ingested by patients with cirrhosis, chronic hepatitis, nephrosis, and ulcerative colitis associated with hypoalbuminemia, it has nutritional and disease-improving effects. That is, an increase in serum total protein and albumin levels, an increase in body weight, and a disappearance of edema are brought about.
(製造例等)
次に、本発明による栄養食の製造例、経口摂取させた場
合の動物及び臨床試験例に関連して本発明を更に詳細に
説明する。(Manufacturing Examples, etc.) Next, the present invention will be described in more detail with reference to manufacturing examples of nutritional foods according to the present invention, animals in the case of oral ingestion, and clinical test examples.
11匠−り
乳アルブミン 69.0 (%)卵ア
ルブミン 17.5ゼラチン
7.5核酸
1.0デキストリン 2.5ソル
ビツト 2.0ポリグリセリン脂肪
酸エステル 0.5上記の諸成分の内で乳アルブミン、
ゼラチン、核酸及びデキストリンを上記の割合で先ず混
合する。この混合物に、ソルビットを水に溶解させたも
のをスプレーして造粒し、次いでポリグリセリン脂肪酸
エステルを水に溶解させたものをスプレーして造粒する
ことにより粉末状の栄養食を製造した。11 Takumi Milk Albumin 69.0 (%) Egg Albumin 17.5 Gelatin
7.5 Nucleic acids
1.0 Dextrin 2.5 Sorbit 2.0 Polyglycerin fatty acid ester 0.5 Among the above ingredients, milk albumin,
Gelatin, nucleic acid and dextrin are first mixed in the above proportions. This mixture was sprayed with sorbitol dissolved in water and granulated, and then polyglycerol fatty acid ester dissolved in water was sprayed and granulated to produce a powdered nutritional food.
この粉末状栄養食は水、牛乳、ジュース、コーヒー、紅
茶等に溶解させて飲用に供することができ、又成形して
菓子類となすための原料とすることができる。This powdered nutritional food can be dissolved in water, milk, juice, coffee, tea, etc. for drinking, or can be molded and used as a raw material for confectionery.
製造例 2
乳アルブミン 3.5(%)卵アル
ブミン 0.8ゼラチン
0.4核酸
0.05デキストリン 0.15
ソルビツト 0.1乳脂肪
2.0ポリグリセリン脂肪酸エス
テル 0.05バニラフレーバー 0
.25水
92,7乳アルブミン3500g、卵アルブミン80
0g 、ゼラチン400g 、核酸50g、デキストリ
ン150g及びツルピッl−+00Jtを95にgの水
に溶解させた。Production example 2 Milk albumin 3.5 (%) Egg albumin 0.8 Gelatin
0.4 nucleic acid
0.05 Dextrin 0.15
Sorbittu 0.1 milk fat
2.0 Polyglycerin fatty acid ester 0.05 Vanilla flavor 0
.. 25 water
92.7 Milk albumin 3500g, egg albumin 80
0 g of gelatin, 400 g of gelatin, 50 g of nucleic acid, 150 g of dextrin, and Tsurupi l-+00Jt were dissolved in 95 g of water.
次いでポリグリセリン脂肪酸エステル50g、乳脂肪2
000g 及びバニラフレーバー250gを上記の溶
液に添加し、配合材料を均一に分散させた後に乳化させ
る。Next, 50g of polyglycerin fatty acid ester, 2g of milk fat
000g and 250g of vanilla flavor are added to the above solution, and the ingredients are uniformly dispersed and then emulsified.
この乳化液を滅菌処理しく145°C13秒間)、均質
機で処理することにより液状の栄養食約100Kg
を得た。この液状栄養食を室温下に24時間放置したが
、離水及び油分溝は何等認められず乳1ヒ安定性の良好
なことが判明した。This emulsion was sterilized at 145°C for 13 seconds) and processed in a homogenizer to produce approximately 100 kg of liquid nutritional food.
I got it. This liquid nutritional food was left at room temperature for 24 hours, but no syneresis or oil grooves were observed, indicating good milk stability.
糺り漣−1
製造例1により得た粉末状栄養食10g と砂糖15
gとを60m1 の水に溶解させた。一方溶きほぐし
た全卵30g を上記の溶液に添加混合させた。この
混合物を型に注入し、弱火で15−20分間蒸煮した。Tadarisen-1 10g of powdered nutritional food obtained according to Production Example 1 and 15g of sugar
g was dissolved in 60 ml of water. On the other hand, 30 g of beaten whole eggs were added to the above solution and mixed. This mixture was poured into molds and steamed on low heat for 15-20 minutes.
次いで、この蒸煮物を器に取り出し、カラメルソースを
かけてプリン菓子とした。Next, this steamed product was taken out into a bowl and caramel sauce was poured over it to make a pudding confectionery.
製造例 4
サラダ油15g と、溶きほぐした全卵10gと、°
砂糖legとを攪拌し、これに、製造例1で得た粉末状
栄養食10g 及び小麦粉25g を添加して充分
に混合する。この混合物を絞出し袋に入れて適当な大き
さに絞出し、天火で焼成してクツキーを得た。Production example 4 15g of salad oil, 10g of beaten whole egg, °
10 g of the powdered nutritional food obtained in Production Example 1 and 25 g of wheat flour were added to the sugar and mixed thoroughly. This mixture was put into a piping bag, squeezed out to an appropriate size, and baked in the oven to obtain kutski.
摂JU成】」生−」−(動物試験)
体重50g 前後であって3 退会のSle:SD系
雌雄性ラット市販の粉末飼料CA−1(日本フレア製)
と水とを自由摂取させて6 日間予備飼育した。(Animal test) Body weight is around 50 g and 3 Sle of withdrawal: SD male and female rats commercially available powdered feed CA-1 (manufactured by Nippon Flare)
The animals were preliminarily reared for 6 days with free access to food and water.
6日間の馴化の後、カゼイン含量Ozの精製飼料を3
週間自由摂取させることにより低蛋白血症ラットとなし
た。この低蛋白血症ラットの作製後、任意に、1群lO
匹からなる2つの試験群(i 及びII) を作製し
た。After 6 days of acclimatization, 3 oz of purified feed with a casein content of 3 oz.
The rats were made hypoproteinemic by giving them ad libitum for weeks. After generation of this hypoproteinemic rat, optionally one group 10
Two test groups (i and II) consisting of animals were created.
被験物質としての栄養食(製造例1)を、又対照物質と
しての大豆蛋白を、カゼイン含量lO%となるように配
合して、それぞれ被験飼料及び対照飼料を調製した。A test feed and a control feed were prepared by blending a nutritional food (Production Example 1) as a test substance and soybean protein as a control substance so that the casein content was 10%.
第1群には被験飼料を、又第1I群には対照飼料をそれ
ぞれ1Sleg 宛3 週間の試験期間にわたり経口
摂取させた。The test feed was orally ingested in Group 1 and the control feed in Group 1I for 1 Sleg each over a 3 week test period.
試験期間中に体重並びに血清中の総蛋白量及びアルブミ
ン量を測定してこれらの変化を調べた結果は第1−3
図のグラフに示される通りであって、第1I群(対照
飼料供与群)と比較して第1群(被験飼料供与群)に関
し体重、血清中の総蛋白量及びアルブミン量が有意に上
昇すること及び低蛋白血症の改善されることが判明した
。The results of measuring body weight, serum total protein amount, and albumin amount during the test period and investigating these changes are shown in Sections 1-3.
As shown in the graph in the figure, the body weight, total protein amount, and albumin amount in serum are significantly increased in Group 1 (test feed group) compared to Group 1I (control feed group). It was also found that hypoproteinemia was improved.
4L隨1匠−と(臨床試験)
a)低アルブミン直症を伴う非代償性肝硬変患者〈男性
、51 歳)に、製造例1による栄養食を1日3回(
20g/日)肝臓食に上乗せして投与摂取させた。(Clinical trial) a) A patient (male, 51 years old) with decompensated liver cirrhosis with direct hypoalbumin was given the nutritional food according to Production Example 1 three times a day (
(20 g/day) was added to the liver meal.
この栄養食の投与前及び投与後に肝機能検査を適宜実施
した結果は、後記の表1に示される通りであった。この
表から、血清中の総蛋白量及びアルブミン量が栄養食の
投与から約1ケ月後に上昇し始めることか判明し、又コ
リンエステラーゼにも上昇傾向が認められ、従って肝で
蛋白やコリンエステラーゼの産生が几進していることが
判明した。尚、上記3種の検査値以外の検査値には有意
の変化が認められなかった。Liver function tests were conducted as appropriate before and after administration of this nutritional food, and the results were as shown in Table 1 below. From this table, it is clear that the total protein and albumin levels in the serum begin to rise about one month after the administration of nutritional food, and that cholinesterase also tends to rise, so that the production of protein and cholinesterase in the liver is reduced. It turned out that it was progressing. Note that no significant changes were observed in test values other than the above three test values.
栄養食の投与から1−2ケ月で栄養状態、病状共に良化
し、又下痢等の副作用は何等認められなかった。One to two months after the administration of the nutritional food, both the nutritional status and the medical condition improved, and no side effects such as diarrhea were observed.
b)栄養状!ぶの良くない大腸炎患者(男性、17歳)
に、製造PA1による栄養食を水、ジュース等に混入さ
せて1日3回(20g/日)投与摂取させた。尚、食事
としては全粥食を摂取させた。b) Nutritional status! A patient with colitis who is not feeling well (male, 17 years old)
The nutritional food manufactured by PA1 was mixed with water, juice, etc., and administered three times a day (20 g/day). In addition, the animals were fed a whole porridge diet.
上記の患者は従来ニレメンタルダイエツトを摂取してい
たが、下痢が多いために栄養状態の良化をもたらし得な
かったのであるが、ニレメンタルダイエツト食を上記の
通りの栄養食と全粥食に代えた結果は後記の表2に肝機
能検査値の推移が示されている通りであって血清中の総
蛋白量及びアルブミン量が増加し、体重も増加して栄養
状態が良化し、病状も徐々に回復した。The patient mentioned above had previously been taking an Elemental diet, but due to frequent diarrhea, it was not possible to improve his nutritional status. The results of this change are as shown in Table 2 below, which shows the changes in liver function test values; total protein and albumin levels in serum increased, body weight increased, nutritional status improved, and disease symptoms also improved. He gradually recovered.
第1図は本発明による栄養食を含有する被験飼料及び大
豆蛋白を含有する対照飼料を低蛋白血症ラッ1へに摂取
させて体重変化の推移を調べた結果を示すグラフ、第2
図は第1図と同様の、但し血清中の総蛋白量変化の推移
を調べた結果を示すグラフ、第3図は第1図と同様の、
但し血清中のアルブミン量変化の推移を調べた結果を示
すグラフである。
特許出願人 株式会社 三和化学研究所第1図
、経過時間C尾)
一:穆、胛騨慴与群
−:灯胴桐竹我与群Figure 1 is a graph showing the results of examining changes in body weight of hypoproteinemic rats 1 after ingesting test feed containing the nutritional food according to the present invention and control feed containing soybean protein;
The figure is the same as Figure 1, except that it is a graph showing the results of examining changes in the total protein amount in serum, and Figure 3 is the same as Figure 1.
However, this is a graph showing the results of examining changes in the amount of albumin in serum. Patent applicant: Sanwa Kagaku Kenkyusho Co., Ltd. Figure 1, elapsed time C tail) 1: Mu, Chikugayo group -: Todo Kiri Chikugayo group
Claims (4)
質と、核酸とを含有していることを特徴とする、栄養食
。(1) A nutritional food characterized by containing protein, mainly animal-derived albumin, carbohydrates, and nucleic acids.
質が1−90%であり、核酸が0.5−10%であるこ
とを特徴とする、特許請求の範囲第1項に記載の栄養食
。(2) Claim 1, characterized in that the amount ratio is 10-90% protein, 1-90% carbohydrate, and 0.5-10% nucleic acid. nutritional food.
ブミンの少なくとも一種であることを特徴とする、特許
請求の範囲第1項に記載の栄養食。(3) The nutritional food according to claim 1, wherein the animal-derived albumin is at least one of milk albumin and egg albumin.
及び植物性蛋白の少なくとも一種を含有していることを
特徴とする、特許請求の範囲第1項に記載の栄養食。(4) The nutritional food according to claim 1, wherein the protein contains at least one of animal protein and vegetable protein as a component other than albumin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61065901A JPS62224259A (en) | 1986-03-26 | 1986-03-26 | Nourishing meal |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61065901A JPS62224259A (en) | 1986-03-26 | 1986-03-26 | Nourishing meal |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS62224259A true JPS62224259A (en) | 1987-10-02 |
Family
ID=13300328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61065901A Pending JPS62224259A (en) | 1986-03-26 | 1986-03-26 | Nourishing meal |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62224259A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02145170A (en) * | 1988-11-29 | 1990-06-04 | Nippon Oil & Fats Co Ltd | Liquid protein assistant food |
WO1991015127A1 (en) * | 1990-04-06 | 1991-10-17 | Otsuka Pharmaceutical Co., Ltd. | High-protein high-viscosity alimentary food composition |
WO2000043035A1 (en) * | 1999-01-19 | 2000-07-27 | Nissho Corporation | Amino acid-containing albumin preparations |
JP2002241283A (en) * | 2001-02-13 | 2002-08-28 | Nippon Zoki Pharmaceut Co Ltd | Hypoalbuminemia-improving medicine |
JP2019083814A (en) * | 2017-11-02 | 2019-06-06 | マルハニチロ株式会社 | Food composition for preventing and/or improving liver dysfunction or hepatic dysfunction, containing dna as an active ingredient |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60120962A (en) * | 1983-12-05 | 1985-06-28 | Idemitsu Kosan Co Ltd | Food and drink enriched with nucleic acid |
JPS60203172A (en) * | 1984-03-29 | 1985-10-14 | Sanwa Kagaku Kenkyusho:Kk | Nutrient food administered orally or through tract |
-
1986
- 1986-03-26 JP JP61065901A patent/JPS62224259A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60120962A (en) * | 1983-12-05 | 1985-06-28 | Idemitsu Kosan Co Ltd | Food and drink enriched with nucleic acid |
JPS60203172A (en) * | 1984-03-29 | 1985-10-14 | Sanwa Kagaku Kenkyusho:Kk | Nutrient food administered orally or through tract |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02145170A (en) * | 1988-11-29 | 1990-06-04 | Nippon Oil & Fats Co Ltd | Liquid protein assistant food |
JPH0560899B2 (en) * | 1988-11-29 | 1993-09-03 | Nippon Oils & Fats Co Ltd | |
WO1991015127A1 (en) * | 1990-04-06 | 1991-10-17 | Otsuka Pharmaceutical Co., Ltd. | High-protein high-viscosity alimentary food composition |
WO2000043035A1 (en) * | 1999-01-19 | 2000-07-27 | Nissho Corporation | Amino acid-containing albumin preparations |
JP2002241283A (en) * | 2001-02-13 | 2002-08-28 | Nippon Zoki Pharmaceut Co Ltd | Hypoalbuminemia-improving medicine |
JP4711523B2 (en) * | 2001-02-13 | 2011-06-29 | 日本臓器製薬株式会社 | Hypoalbuminemia improving agent |
JP2019083814A (en) * | 2017-11-02 | 2019-06-06 | マルハニチロ株式会社 | Food composition for preventing and/or improving liver dysfunction or hepatic dysfunction, containing dna as an active ingredient |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4112123A (en) | Nutritionally balanced single food composition and method of production | |
JPS63502558A (en) | Sweet confectionery products and their manufacturing methods | |
KR960003888B1 (en) | Liquid nutritional formula for glucose intolerance | |
JP2003533438A (en) | Carbohydrate formulations for enhancing immune response (prebiotic adjuvants) | |
CA2261708A1 (en) | Composition of pyruvate and protein and method for increasing protein concentration in a mammal | |
KR20070112811A (en) | Amino acid composition for improving glucose tolerance | |
JPS6236645B2 (en) | ||
WO1998008402A1 (en) | Nutritional formula for phenylketonuria patients | |
US20030124198A1 (en) | Nutritional or therapeutic supplement and method | |
WO1986007262A1 (en) | High caloric, high fat dietary formula | |
JP3907098B2 (en) | Nutritional drink or jelly | |
US5849335A (en) | Composition and method for providing glutamine | |
JPH0347829B2 (en) | ||
JP3544493B2 (en) | Nutrition composition for infants | |
JPH0394655A (en) | Nutrient feeding composition | |
KR0160272B1 (en) | High-protein, high-viscosity alimentary food composition | |
JPH11263733A (en) | Lipid metabolism improver | |
ES2219928T5 (en) | ACCELERATION METHOD OF THE DIGESTION SPEED OF A PROTEIN AND ITS EMPLOYMENT. | |
JPS62224259A (en) | Nourishing meal | |
JPS6322525A (en) | Hematinic | |
EP0665012B1 (en) | Antiallergy agent and nutritional composition containing glutamine | |
US6797290B2 (en) | Compositions for appetite control and related methods | |
JPH08259461A (en) | Lipometabolism improver | |
JP3285959B2 (en) | Liquid preparation nutritional food for long-term medical care patients | |
AU2002325007A1 (en) | Compositions for appetite control and related methods |